Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trialShow full item record
| Title | Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial |
|---|---|
| Author | Johnson, Theodore S.; MacDonald, Tobey J.; Pacholczyk, Rafal; Aguilera, Dolly; Al-Basheer, Ahmad; Bajaj, Manish; Bandopadhayay, Pratiti; Berrong, Zuzana; Bouffet, Eric; Castellino, Robert C.; Dorris, Kathleen; Eaton, Bree R.; Esiashvili, Natia; Fangusaro, Jason R.; Foreman, Nicholas; Fridlyand, Diana; Giller, Cole; Heger, Ian M.; Huang, Chenbin; Kadom, Nadja; Kennedy, Eugene P.; Manoharan, Neevika; Martin, William; McDonough, Colleen; Parker, Rebecca S.; Ramaswamy, Vijay; Ring, Eric; Rojiani, Amyn; Sadek, Ramses F.; Satpathy, Sarthak; Schniederjan, Matthew; Smith, Amy; Smith, Christopher; Thomas, Beena E.; Vaizer, Rachel; Yeo, Kee Kiat; Bhasin, Manoj K.; Munn, David H. |
| Date | 9/16/2023 |
| Description | Background. Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy.Methods. We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG). Separate dose-finding arms were performed for indoximod in combination with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles), or with palliative conformal radiation. Blood samples were collected at baseline and monthly for single-cell RNA-sequencing with paired single-cell T cell receptor sequencing.Results. Eighty-one patients were treated with indoximod-based combination therapy. Median follow-up was 52 months (range 39-77 months). Maximum tolerated dose was not reached, and the pediatric dose of indoximod was determined as 19.2 mg/kg/dose, twice daily. Median overall survival was 13.3 months (n = 68, range 0.2-62.7) for all patients with recurrent disease and 14.4 months (n = 13, range 4.7-29.7) for DIPG. The subset of n = 26 patients who showed evidence of objective response (even a partial or mixed response) had over 3-fold longer median OS (25.2 months, range 5.4-61.9, p = 0.006) compared to n = 37 nonresponders (7.3 months, range 0.2-62.7). Four patients remain free of active disease longer than 36 months. Single-cell sequencing confirmed emergence of new circulating CD8 T cell clonotypes with late effector phenotype.Conclusions. Indoximod was well tolerated and could be safely combined with chemotherapy and radiation. Encouraging preliminary evidence of efficacy supports advancing to Phase II/III trials for pediatric brain tumors. |
| Link | https://doi.org/10.1093/neuonc/noad174
https://repository.tcu.edu/handle/116099117/65963 |
| Department | Burnett School of Medicine |
Files in this item
This item appears in the following Collection(s)
- Research Publications [1008]
© TCU Library 2015 | Contact Special Collections |
HTML Sitemap